Teva slumped to $590m negative EBITDA in the second quarter, after putting pen to paper on a multi-billion-dollar nationwide agreement in principle to settle opioid-related claims against the company. However, this does not paint the full picture.
While Teva’s P&L for Q2 did include a $729m legal loss contingency “mainly related to an update of the estimated...






